Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Trial Profile

CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cerdulatinib (Primary)
  • Indications Anaplastic large cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CELTIC-1
  • Sponsors Portola Pharmaceuticals

Most Recent Events

  • 10 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 26 Feb 2020 According to an Portola Pharmaceuticals Media Release, the company has decided not to initiate this trial until a partner is identified.
  • 05 Nov 2019 According to an Portola Pharmaceuticals Media Release, company plans to launch a cerdulatinib registration study in peripheral T-cell lymphoma (PTCL) in early 2020 and will present updated data at the ASH meeting in December

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top